SymbolIMMP
NameIMMUTEP LTD
SectorHEALTH CARE
RegionOceania
IndustryPharmaceutical Preparations
AddressLEVEL 32, SUITE 32.07 AUSTRALIA SQUARE, SYDNEY,, C3 NSW 2000
Telephone612 8315 7003
Fax
Email
Websitehttps://www.immutep.com
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK0001506184
Description

Immutep Ltd. is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3s unique ability to stimulate or suppress the immune response. Immuteps lead clinical candidate, eftilagimod alpha (efti), is a soluble LAG-3 protein and first-in-class MHC Class II agonist that stimulates both innate and adaptive immunity to fight cancer.

Additional info from NASDAQ:
Immutep Ltd. is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3s unique ability to stimulate or suppress the immune response. Immuteps lead clinical candidate, eftilagimod alpha (efti), is a soluble LAG-3 protein and first-in-class MHC Class II agonist that stimulates both innate and adaptive immunity to fight cancer.

2026-05-15 00:02

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP

Read more
2026-05-12 13:00

IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm

Read more
2026-05-10 13:00

Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

Read more
2026-05-07 14:00

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP

Read more
2026-05-06 20:26

IMMP Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Immutep Limited

Read more
2026-05-06 16:24

Rosen Law Firm Urges Immutep Ltd. (NASDAQ: IMMP) Stockholders to Contact the Firm for Information About Their Rights

Read more
2026-05-05 21:15

Investor Notice: Robbins LLP Informs Investors of the Immutep Limited Class Action

Read more
2026-05-05 02:22

IMMP attributes changed: Attr: Fin_status N -> D;

Read more
2026-05-05 02:22

NASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.

Read more
2026-05-05 01:45

NASDAQ symbol attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.

Read more